2012
Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide
Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, Silvia A, Miller PF. Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide. PLOS ONE 2012, 7: e30479. PMID: 22279595, PMCID: PMC3261206, DOI: 10.1371/journal.pone.0030479.Peer-Reviewed Original ResearchMeSH KeywordsAdamantaneAntitubercular AgentsDiarylquinolinesDrug MonitoringDrug Therapy, CombinationEthylenediaminesExtensively Drug-Resistant TuberculosisHumansMicrobial Sensitivity TestsMycobacterium tuberculosisNitroimidazolesOxazolidinonesPyrazinamideQuinolinesReproducibility of ResultsTime FactorsConceptsPNU-100480Whole blood culturesPA-824Blood culturesWhole-blood bactericidal activityBactericidal activityStandard TB therapyDihydroxy vitamin DIntracellular M. tuberculosisBlood bactericidal activityCumulative activityPZA-resistant strainsHigh therapeutic concentrationsActive regimensTB regimensNew regimensTB therapyVitamin DOral dosingTherapeutic concentrationsDrug combinationsPharmacokinetic dataRegimensIndividual drugsTMC207
2011
Low Prevalence of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates among Connecticut Veterans
Fink SL, Martinello RA, Campbell SM, Murray TS. Low Prevalence of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates among Connecticut Veterans. Antimicrobial Agents And Chemotherapy 2011, 56: 582-583. PMID: 22064529, PMCID: PMC3256079, DOI: 10.1128/aac.05024-11.Peer-Reviewed Original ResearchConceptsHeterogeneous vancomycin-intermediate Staphylococcus aureusMethicillin-resistant Staphylococcus aureusHeterogeneous Vancomycin-Intermediate Staphylococcus aureus IsolatesVancomycin-intermediate Staphylococcus aureusLow-prevalence populationsStaphylococcus aureus isolatesStaphylococcus aureusPrevalence populationsRoutine screeningVeterans HospitalLow prevalenceAureus isolatesCurve analysisResistance detectionAureusIsolatesPatientsHospitalPrevalenceEtest
2010
Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis
Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, Ladutko L, Campbell S, Miller PF. Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis. Antimicrobial Agents And Chemotherapy 2010, 55: 567-574. PMID: 21078950, PMCID: PMC3028776, DOI: 10.1128/aac.01179-10.Peer-Reviewed Original ResearchMeSH KeywordsAcetamidesAdolescentAdultAnimalsAntitubercular AgentsArea Under CurveDose-Response Relationship, DrugDrug Administration ScheduleHumansLinezolidMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisOxazolidinonesPyrazinamideRatsSerum Bactericidal TestTreatment OutcomeTuberculosisYoung AdultConceptsPNU-100480Whole-blood bactericidal activityMultiple ascending dosesDays of dosingSerious global health threatWhole blood culturesBactericidal activityGlobal health threatM. tuberculosis growthAscending dosesSixth cohortNew tuberculosis treatmentsPlasma drugTuberculosis treatmentPlasma concentrationsSafety signalsHealthy volunteersDose selectionRoutine safety testsNew treatmentsDay 27TuberculosisMycobacterium tuberculosisDosesHealth threat